Neon therapeutics, inc. (NTGN)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-16,598

-17,840

-18,980

-21,932

-21,024

-23,123

-18,391

-18,900

-16,520

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense

400

344

467

433

400

400

400

370

330

Non-cash lease expense

314

306

300

293

287

-

-

-

0

Net amortization of premiums and discounts on marketable securities

0

0

-13

-13

21

0

200

-37

-159

Stock-based compensation expense

1,669

1,523

2,034

2,054

1,729

1,514

1,643

1,422

1,650

Loss on disposal of property and equipment

-

-

-

-

-

-4

-11

-1

-9

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

114

-188

38

-351

233

-153

515

-100

78

Other long-term assets

-6

-7

-7

-6

42

0

0

0

-125

Accounts payable

1,341

-233

-816

-1,262

0

1,461

1,622

-1,040

-92

Accrued expenses and other liabilities

-1,027

496

597

203

-2,012

1,713

-534

3,395

-512

Lease liabilities

-295

-288

-267

-260

-254

-

-

-

0

Net cash used in operating activities

-14,280

-15,463

-16,713

-20,081

-21,155

-17,886

-15,990

-14,623

-14,929

Cash flows from investing activities:
Purchases of marketable securities

-

-

-

-

-

0

60,949

0

11,990

Sales and maturities of marketable securities

0

0

14,700

17,281

18,700

10,300

7,800

9,800

15,650

Purchases of property and equipment

9

-183

62

179

1,026

614

333

817

1,458

Net cash (used in) provided by investing activities

-9

183

14,638

17,102

17,674

9,686

-53,482

8,983

2,202

Cash flows from financing activities:
Proceeds from exercise of stock options

0

0

70

0

45

5

171

228

0

Payments for repurchase of common stock for employee tax withholdings

59

-

-

-

0

-

-

-

-

Payment of initial public offering costs

-

-

-

-

-

35

723

1,216

1,091

Net cash (used in) provided by financing activities

-59

397

68

0

45

-30

-553

92,012

-1,091

Net decrease in cash, cash equivalents and restricted cash

-14,348

-14,883

-2,007

-2,979

-3,436

-8,230

-70,025

86,372

-13,818

Supplemental disclosure of non-cash items:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

0

0

3,185

3,186

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

0

1,003

Purchases of property and equipment included in accounts payable and accrued expenses

0

0

0

-168

168

25

400

-347

419